NCT00761696

A Phase 1 Study of IPI-926 in Patients With Advanced and/or Metastatic Solid Tumor Malignancies

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 94 (actual)
• Sponsor: Infinity Pharmaceuticals, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The primary objectives of the study are: * To determine the safety and the maximum tolerated dose (MTD) of IPI-926 * To examine the pharmacokinetic parameters of IPI-926 and its characterized major metabolite(s) * To recommend a dose and schedule of IPI-926 for subsequent studies

Detailed description

Study IPI-926-01 is a Phase 1, open-label, dose-escalation study in patients with advanced and/or metastatic solid tumor malignancies.

Conditions

• Neoplasms

Interventions

Type	Name	Description
DRUG	IPI-926	Oral daily dosing

Timeline

• Start date: 2008-09-01
• Primary completion: 2012-04-01
• Completion: 2012-04-01
• First posted: 2008-09-29
• Last updated: 2012-06-21

Locations

5 sites across 2 countries: United States, Canada